Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04656470 · ClinicalTrials.gov registry record · Phase 2
Neuroimaging Study of Dexmedetomidine-Induced Analgesia
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT04656470: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04656470 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04656470, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Neuroimaging data will be collected for patients that are given low doses of dexmedetomidine in order to understand its analgesic effects.
Interventions
- DRUG Dexmedetomidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2025-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04656470
The ClinicalTrials.gov registry entry for NCT04656470 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexmedetomidine is the first listed.
NCT04656470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04656470 about?
NCT04656470 is a clinical study titled "Neuroimaging Study of Dexmedetomidine-Induced Analgesia". Neuroimaging data will be collected for patients that are given low doses of dexmedetomidine in order to understand its analgesic effects.
What is the current status of trial NCT04656470?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2022-03-04. Estimated completion is 2025-05-27.
What interventions are being tested in trial NCT04656470?
The interventions under investigation include: Dexmedetomidine (DRUG).
Who is sponsoring clinical trial NCT04656470?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.